A 5 ‐day regimen of azacitidine for lower‐risk myelodysplastic syndromes (RA or RARS): a prospective single‐arm phase 2 trial

Cancer Science,Volume 0, Issue ja, -Not available-.

Source: Cancer Science - July 14, 2018 Category: Cancer & Oncology Authors: Yasuyoshi Morita , Yasuhiro Maeda , Terufumi Yamaguchi , Fumiaki Urase , Shuhei Kawata , Hitoshi Hanamoto , Kazuo Tsubaki , Jun Ishikawa , Hirohiko Shibayama , Itaru Matsumura , Mitsuhiro Matsuda Source Type: research